Unichem Labs gets USFDA nod to Baclofen Tablets for spasticity relief
Baclofen Tablets are indicated for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.
Mumbai: Drug Firm Unichem Laboratories Limited has received ANDA approval for its Baclofen Tablets, USP, 10 mg and 20 mg from the United States Food and Drug Administration (USFDA) to market a generic version of LIORESAL® (Baclofen) Tablets, 10 mg and 20 mg of Novartis Pharmaceuticals Corp.
Baclofen Tablets are indicated for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. The product will be commercialized from Unichem's Ghaziabad Plant.
Read also: Unichem Labs gets USFDA EIR for Roha API facility
Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.
Read also: Unichem Labs gets USFDA nod to Cyclobenzaprine Hydrochloride Tablets to treat muscle spasm
